Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 60, Issue 3, 2013, Pages 420-427

  Volejnikova, Jana ^a   Mejstrikova, Ester ^a   Dörge, Petra ^b   Meissner, Barbara ^b   Zimmermannova, Olga ^a   Svojgr, Karel ^a   Stanulla, Martin ^b   Cario, Gunnar ^b   Schrappe, Martin ^b   Stary, Jan ^a   Hrusak, Ondrej ^a   Trka, Jan ^a   Fronkova, Eva ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Acute lymphoblastic leukemia (ALL); Childhood; Ikaros; IKZF1; Minimal residual disease (MRD)

Indexed keywords

BCR ABL PROTEIN; IKAROS TRANSCRIPTION FACTOR;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT;

CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; IKAROS TRANSCRIPTION FACTOR; MALE; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS; TRANSCRIPTOME;

EID: 84872469678     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24299     Document Type: Article

References (32)

1. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214.
2. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
3. Fronkova E, Mejstrikova E, Avigad S, et al. Minimal residual disease (MRD) analysis in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Is it possible to avoid MRD testing? Leukemia 2008; 22: 989-997.
4. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
5. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol 2009; 10: 125-134.
6. Waanders E, van der Velden VH, van der Schoot CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011; 25: 254-258.
7. Buitenkamp TD, Pieters R, Gallimore NE, et al. Outcome in children with Down's syndrome and acute lymphoblastic leukemia: Role of IKZF1 deletions and CRLF2 aberrations. Leukemia 2012; DOI: 10.1038/leu.2012.84 [Epub ahead of print].
8. Tonnelle C, Dijon M, Moreau T, et al. Stage specific over-expression of the dominant negative Ikaros 6 reveals distinct role of Ikaros throughout human B-cell differentiation. Mol Immunol 2009; 46: 1736-1743.
9. Molnar A, Georgopoulos K. The Ikaros gene encodes a family of functionally diverse zinc finger DNA-binding proteins. Mol Cell Biol 1994; 14: 8292-8303.
10. Nakase K, Ishimaru F, Avitahl N, et al. Dominant negative isoform of the Ikaros gene in patients with adult B-cell acute lymphoblastic leukemia. Cancer Res 2000; 60: 4062-4065.
11. Takanashi M, Yagi T, Imamura T, et al. Expression of the Ikaros gene family in childhood acute lymphoblastic leukaemia. Br J Haematol 2002; 117: 525-530.
12. Klein F, Feldhahn N, Herzog S, et al. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene 2006; 25: 1118-1124.
13. Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: Implications for a new mechanism of resistance. Blood 2008; 112: 3847-3855.
14. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
15. Cario G, Izraeli S, Teichert A, et al. High interleukin-15 expression characterizes childhood acute lymphoblastic leukemia with involvement of the CNS. J Clin Oncol 2007; 25: 4813-4820.
16. Zaliova M, Fronkova E, Krejcikova K, et al. Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR/ABL-positive ALL: Implications for residual disease monitoring. Leukemia 2009; 23: 944-951.
17. Iacobucci I, Lonetti A, Cilloni D, et al. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica 2008; 93: 1814-1821.
18. Panaro NJ, Yuen PK, Sakazume T, et al. Evaluation of DNA fragment sizing and quantification by the agilent 2100 bioanalyzer. Clin Chem 2000; 46: 1851-1853.
19. Mueller O, Hahnenberger K, Dittmann M, et al. A microfluidic system for high-speed reproducible DNA sizing and quantitation. Electrophoresis 2000; 21: 128-134.
20. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-A Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
21. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258-1264.
22. Fairbrother WG, Yeh RF, Sharp PA, et al. Predictive identification of exonic splicing enhancers in human genes. Science 2002; 297: 1007-1013.
23. Mejstrikova E, Volejnikova J, Fronkova E, et al. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica 2010; 95: 928-935.
24. Arico M, Valsecchi MG, Rizzari C, et al. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: Insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy. J Clin Oncol 2008; 26: 283-289.
25. Dworzak MN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002; 99: 1952-1958.
26. Mejstrikova E, Fronkova E, Kalina T, et al. Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry. Pediatr Blood Cancer 2010; 54: 62-70.
27. van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-611.
28. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27: 5168-5174.
29. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110-114.
30. Marcais A, Jeannet R, Hernandez L, et al. Genetic inactivation of Ikaros is a rare event in human T-ALL. Leuk Res 2010; 34: 426-429.
31. Bellavia D, Mecarozzi M, Campese AF, et al. Notch3 and the Notch3-upregulated RNA-binding protein HuD regulate Ikaros alternative splicing. EMBO J 2007; 26: 1670-1680.
32. Zhou F, Mei H, Jin R, et al. Expression of Ikaros isoform 6 in chinese children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2011; 33: 429-432.